In the latest development in oncology research, AstraZeneca’s PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical significance for its primary endpoint of progression-free survival (PFS) in treating patients with unresectable, Stage III non-small cell lung cancer (NSCLC). Imfinzi’s Established Role and PACIFIC-2’s Goals Despite this outcome, […]
AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the updated results from the HIMALAYA Phase 3 trial. An unparalleled one in four patients were still alive four years after treatment with this novel combination therapy, marking the longest survival […]
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small cell lung cancer (NSCLC). The pharma giant said that the mid-stage clinical trial showed the experimental combinations to have improved progression-free survival (PFS) as well as objective response rate (ORR). […]
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). This recommendation paves the way for a new treatment option for […]
Advaxis, a biotech firm based in New Jersey, announced a significant regulatory update as the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on its Phase 1/2 trial. This trial is exploring the effectiveness of a combination therapy using Axalimogene Filolisbac (AXAL) and Durvalumab in treating advanced, recurrent, or refractory […]
